PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 13, 2006Journal of Medicinal Chemistry698 citationsOpen Access

Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction

View Full Paper
KDKe DingChina Pharmaceutical UniversityYLYipin LuSuzhou Traditional Chinese Medicine HospitalZNZaneta Nikolovska‐ColeskaUniversity of Southern California

Key Points

Key points are not available for this paper at this time.

Abstract

Potent, specific, non-peptide small-molecule inhibitors of the MDM2-p53 interaction were successfully designed. The most potent inhibitor (MI-63) has a K(i) value of 3 nM binding to MDM2 and greater than 10,000-fold selectivity over Bcl-2/Bcl-xL proteins. MI-63 is highly effective in activation of p53 function and in inhibition of cell growth in cancer cells with wild-type p53 status. MI-63 has excellent specificity over cancer cells with deleted p53 and shows a minimal toxicity to normal cells.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ding et al. (2006) studied this question.

synapsesocial.com/papers/69df2b143b0ba53fb37a1be0https://doi.org/10.1021/jm051122a
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors2005 · 654 citations
  2. 2An inhibitor of Bcl-2 family proteins induces regression of solid tumours2005 · 3,420 citations
  3. 3The p53-mdm-2 autoregulatory feedback loop.1993 · 1,803 citations
  4. 4Synthesis of spirooxindoles via asymmetric 1,3-dipolar cycloaddition2005 · 64 citations
  5. 5Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen1997 · 6,769 citations